✦ LIBER ✦

A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck

✍ Scribed by Brandon Whitcher; Volker J. Schmid; David J. Collins; Matthew R. Orton; Dow-Mu Koh; Isabela Diaz de Corcuera; Marta Parera; Josep M. del Campo; Nandita M. deSouza; Martin O. Leach; Kevin Harrington; Iman A. El-Hariry

Publisher: Springer
Year: 2011
Tongue: English
Weight: 633 KB
Volume: 24
Category: Article
ISSN: 0968-5243
DOI: 10.1007/s10334-010-0238-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of mitoxantrone in adva

A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck

✍ H. Wheeler; R. L. Woods; J. Page; J. Levi 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 186 KB

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two

Phase II study of amonafide in the treat

Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck

✍ Fred Rosen; Everett E. Vokes; Thomas Lad; Merrill Kies; James Wade; Lary J. Kilt 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 299 KB

Phase 2 study of dasatinib in the treatm

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

✍ Heather D. Brooks; Bonnie S. Glisson; B. Nebiyou Bekele; Lawrence E. Ginsberg; A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Phase II trial of carboplatin and vinbla

Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck

✍ S. EL Sayed; R. P. Symonds; A. G. Robertson; J. Paul; J. McGarva 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 217 KB

A phase II study of adriamycin in previo

A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck

✍ Melody A. Cobleigh; James H. Hill; Patricia A. Gallagher; Lawrence J. Kukla; Tho 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 2 views

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m\* at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 eval

A multicenter phase II study of tgDCC-E1

A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma

✍ Doug Villaret; Bonnie Glisson; Daniel Kenady; Ehab Hanna; Mary Carey; Lyon Gleic 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Background: The anti-cancer gene, e1a, can be complexed to a lipid carrier, dc-cholesterol:dope, to form tgdcc-e1a, which can be injected directly into tumors. ## Methods: Twenty-four patients with recurrent, unresectable, head and neck cancer were treated with intratumoral injections of tgdcc